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was 27.0 ± 14.7 months. The commonest reason for 
discontinuation was desire for pregnancy (36.1%) 
followed by those who changed to other methods 
(27.6%). Menstrual irregularity was the commonest 
side effect of implanon that led to removal.
Seven in-treatment pregnancies occurred giving a 
pearl index of 0.35 although only one pregnancy was 
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ABSTRACT
Background: the contraceptive prevalence (CPR) in sub-Saharan Africa is low at 8-10% for over a decade. 
There is also the dominance of the less effective short-acting methods such as pills and injectables. The low 
CPR is the direct cause of the high total fertility of 5.7 in Nigeria. The use of contraception is the single most 
dominant contributory factor in fertility declines world-wide. This is especially more true with the use of 
long acting reversible contraceptive methods like implanon which has the potential to reduce the global 
burden of disease and mortality associated with a high total fertility rate.
Objective: our aim was to analyse and determine the socio-demographic profiles of implanon acceptors and 
the factors associated with continuation or discontinuation of its use in the family planning programme of 
the Jos University Teaching Hospital, Jos Nigeria.
Materials and Methods: This was a retrospective review carried out between March 2007 and March 2014 
at the Jos University Teaching Hospital, Jos Nigeria
Results: during the study period, 1482 women accepted implanon with about 85.8% having regular 
menstrual cycles. Sixty-one percent of these women were breastfeeding at insertion. Their mean age was 31 
years with a range of 16 to 53. Christianity was the religion of 87.8% with 12.2% being Muslims. Just under 
half had tertiary education with over a third having attended secondary school. About 26.7% had no future 
fertility desires. Over 75% had previously used a contraceptive method. The mean parity in this study was 
3.2 with a range of 0 to 12. The mean number of children alive was 2.9.
Both the systolic and diastolic blood pressures were little affected by the use of implanon. However there 
was a mean weight gain among 900 of the women who came for follow up of 2.4 kg. However the weight 
change was highly variable with about a third of women losing between 1 to 30 kg, 10% not having any net 
changes and over 61% having a net weight gain of between 1 to 26 kg. About 3.8% had their implanon 
removed because of weight gain.
The percentage loss to follow up was 28.2%. The 900 women who had follow up were exposed to the 
implanon for 2006.6 woman-years or 24,079 cycles. The mean number of months of exposure to the implant 
CONCLUSION: Accepting implanon was 
influenced by the educational attainment and 
religion of the women in our unit. The desire for 
another pregnancy was the commonest reason for 
discontinuation. However, menstrual irregularity 
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was the commonest side effect of the implant that led to its removal especially in the first six months after 
insertion.
Keywords: Implanon (etonogestrel) contraceptive, continuation rates, discontinuation, reason for 
discontinuation.
INTRODUCTION 
dominant contributory factor in fertility declines 
9-13world-wide .  It has amply been demonstrated 
to be very cost effective and relatively 
inexpensive in comparison to the consequences 
1, 14of unintended pregnancies . The lifetime 
likelihood of dying from pregnancy in sub-
15Saharan Africa is 1 in 16 . This risk is 
particularly increased for women less than 25 
years of age because this population constitutes 
16about 55% of unsafe abortions in the region . 
The unfettered access and use of effective 
methods of contraception especially the long 
acting reversible contraceptives (LARC) will 
help to reduce this global burden of disease and 
1mortality . However, the choice of contraceptive 
method by a woman depends on a constellation 
of different factors: the woman's educational 
attainment and fertility desires at a given time, 
the contraceptive method mix available to her, 
her awareness of them and where she can obtain 
them, their cost, the distance to the facility and 
the influence of the media and perceived general 
17-19acceptability of family planning . In addition, 
whether the method is user- or provider-
dependent, its influence on the spontaneity of 
coitus, return to fertility after stoppage of its use, 
protection against sexually transmitted 
infections and the length of protection it offers 
against pregnancy are other factors that directly 
20influence personal preferences . 
Implanon a single-rod non-biodegradable 
implantable contraceptive containing 68 mg of 
etonogestrel is a long-acting contraceptive 
The use of modern contraceptive methods in 
sub-Saharan Africa has remained relatively low 
at 8-10% for over a decade. Equally disturbing is 
the fact that within this low contraceptive 
prevalence (CPR) is an over-dominance of the 
less effective short-acting methods such as pills 
1, 2
and injectables . These short-acting methods 
require frequent re-dosing and therefore suffer a 
constant threat from commodity stock outs, 
difficulty of frequent clinic visits occasioned 
with long waiting times for the clients, the 
unending encounter with the bad ttitudes of 
health care workers and the ambivalence 
1
towards pregnancy/ contraception . The low 
CPR of 6.8% reported in Nigeria in 1999 and 
3
currently 9.7%  is the direct cause of the high 
total fertility of 5.7 with some areas in the North 
4
western part of the country reaching 7.3 . This is 
because fertility level is inversely related to the 
5,6
contraceptive prevalence rate . This low CPR is 
partly the consequence of the lack of proper 
information and access to modern contraceptive 
methods, desire for large family size, the 
existence of preconceived ideas and taboos, the 
inordinate fear of perceived side effects of 
contraceptives, the dominant power of men to 
decide for contraception and polygyny. 
Polygyny sets women in competition with the 
co-wives to deliver the most number of children 
in the hope of securing maximally from the 
7, 8
husband's resources in the event of his death .
The use of contraception is the single most 
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method with contraceptive efficacy of three 
years and a quick return to fertility after 
21
removal . Like other implants, its potential 
22
benefits remained largely underutilized . 
Knowledge about implants is frequently low, 
even in areas where there is good general 
23
awareness of modern contraceptives . Most of 
the information currently used to counsel clients 
in our sub-region are from studies in Europe, 
24-26
Asia, Australia and the Americas  .We sought 
to analyse and determine the socio-demographic 
profiles of implanon acceptors and the factors 
associated with continuation or discontinuation 
of its use in the family planning programme of 




Design and period of the study
This was a retrospective study carried out 
between March 2007 and March 2014 at the 
Family Planning Unit of the Department of 
Obstetrics and Gynaecology, Jos University 
Teaching Hospital, Jos Nigeria. It was designed 
to assess the socio-demographic profile, the 
continuation rates, the loss to follow-up rate and 
various reasons given for removal amongst 
users of implanon
Subjects
Implanon was inserted to all women who had no 
contraindication to its use, who opted for the 
implant over all other available method after a 
comprehensive counselling on the method.
The exclusion criteria were known or suspected 
pregnancy, hypersensitivity to the drug and 
being within 6 weeks of delivery.
Implanon, like all other contraceptive methods 
was provided free by the Federal Ministry of 
Health except a service charge of about $6 for 
consumables.
Information gathered
The information on the socio-demographic 
characteristics, Obstetric and Gynaecological 
Histories, medical history, pre-existing chronic 
conditions, drug history, and previous use of 
contraception were collected. Also, the dates of 
insertion and removal, complication and 
adverse effects from the use of the device, 
discontinuation, reasons for discontinuation and 
duration of use of the implant were recorded. 
The blood pressure and weight were measured at 
each visit. A systolic blood pressure of 
140mmHg or more and a diastolic of 90mmHg 
or more were considered as the cut off for 
hypertension. Since the efficacy of implanon is 
said to decrease with any weight above 70 kg, 
any weight above this was taken as the cut off 
point for normal weight in our study. A urine 
pregnancy test was usually carried to rule out 
any existing pregnancy before insertion. A urine 
pregnancy test was also repeated once there was 
any suspicion of a pregnancy with the implant in 
situ. If the pregnancy test became positive while 
using the implant, an ultrasound was carried out 
to date the pregnancy.
Follow-up
The clients were followed up from insertion of 
implanon to its removal with yearly scheduled 
monitoring visits. Free access to the unit was 
made to the clients for any unscheduled visits if 
they had any complaints with the implant or 
required its removal at any time.
During the follow up visits, scheduled or 
unscheduled, the women were asked whether 
they have had any problems or side effects 
resulting from the use of the implant.
The time (in months) from the date of insertion 
to the last visit at the clinic was documented. 
Those women who were not seen in the clinic 
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The majority of the women 1164 (85.8%) had 
regular menstrual cycle at baseline and the 
remaining 193 (14.2%) had irregular menstrual 
flow. About sixty one percent of the women were 
breastfeeding at the time of implanon insertion 
while the rest (38.7%) were not.
again after insertion were considered as loss to 
follow up. Every woman who had at least one 
follow up visit after the month in which the 
implant was inserted was therefore included in 
the calculation of period exposed to implanon. 
The duration of exposure to implanon was 
expressed in woman-years and the total number 
of 28-day cycles. A woman-year refers to a 
period of 365.25 days and this is the equivalence 
of roughly 13 cycles. 
The Contraceptive efficacy of implanon was 
determined by the number of in-treatment 
pregnancies that occurred. The pregnancy rate 
was calculated using the Pearl Index (PI) which 
is the number of in-treatment pregnancies per 
100 woman-years of exposure.
Statistical analysis 
The sample size of our study was based on 
clinical feasibility and not any formal statistical 
power calculations. Every woman that accepted 
implanon for contraception was therefore 
included in the analysis of the socio-
demographic characteristics.
Descriptive and analytic statistics were carried 
out on all data where appropriate using Epi info 
version 3.5.1 (CDC, Atlanta, GA USA). The 
descriptive statistics were percentage, mean, 
median, standard deviation, range and 95% 
confidence interval. For quantitative variables, 
a comparative test of averages was carried out 
and a chi-squared test was performed for the 
qualitative variables. Significance was 
established at the level of 0.05 for all analyses.
RESULTS
During the study period, 1482 women accepted 
implanon over all other available family 
planning methods. Table 1 shows the socio-
demographic characteristics of these women. 
Table 1 Socio-demographic characteristics of 
implanon acceptors
Variable Implanon(N=1482 )
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EDUCATIONAL STAT US 
No Formal education 22   1.6
Primary Education 179 13.0
Secondary Education 504 36.7
Tertiary Education 671 48.8
Over a quarter of the women (26.7%) had no 
further wish for bearing more children at 
insertion while about 73.3% was using implanon 
for child spacing. More than three quarters of the 
implanon acceptors had used at least one form of 
contraceptive method previously while about 
22.4% of them were first time users of 
contraceptives. 
The delivery history of the implanon acceptors is 
depicted in Table 2. Most women accepted 
implanon after a parity of 3. Less than 1% of the 
women were nulliparous. 
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The mean (± SD) Systolic Blood Pressure (SBP) 
at baseline was 113.1 (± 12.2) mmHg with 4.2% 
of the women having a SBP ≥140 mmHg. By the 
last known measurement during follow up, the 
mean SBP (± SD) became 114.7 (±13.6) mmHg 
with 7.1% of the clients having SBP ≥ 140 
mmHg. This represented a mean increase of 1.6 
mmHg in the SBP. The mean Diastolic Blood 
Pressure (DBP) at baseline was 75.6 mmHg with 
16.3% of the women having a DBP ≥90. By the 
last known measurement during implanon use, 
the mean (± SD) DBP increased to 76.3 (±11.0) 
with 19.1% of the women having DBP ≥90 
mmHg. The average increase in DBP was 
therefore 0.7 mmHg.
Table 3 shows the different body weight 
categories and their frequency of occurrence. At 
baseline over a quarter of the women weighed 
more than 70 kg. However, by the last 
documented follow up visit, over a third of the 
women weighed more than 70 kg. The mean 
weight gain for all the 900 women who had at 
least one follow up visit was 2.4 Kg. About a 
third (28.8%) of the women had a net weight loss 
ranging from -1kg to -30 kg. Exactly 10.0% had 
no net change in weight. The remainder of the 
women (61.2%) had a net increase in body 
weight ranging from 1kg to 26 kg (36% had an 
increase less than 5kg while 25.2% had more 
than 5kg increase). The mean change in body 
weight after years 1, 2, 3, and 4 were 0.8kg, 
1.6kg, 3.2kg and 3.3 kg respectively. About 
3.8% of the women who had their implanon 
removed were on account of weight gain (Table 
4 below).
Table 3 showing the number and percentages of 
the different weight categories at baseline and at 
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Children 
: showing the delivery records of the implanon acceptors











































































BASELINE WEIGHTFINAL WEIGHT FOUND
WEIGHT GROUP(kg) No. % No. %   
31-40 7 0.8 3 0.4
41-50 96 10.7 82 9.6











































121-130 0 0 1 0.1
Mean (± SD) 64.4±12.1 Kg 66.9±13.3 Kg
Range 36 -112 Kg 35 -135 Kg
Median 63 Kg 66 Kg
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Two hundred and forty six women accepted 
implanon within the last year of the study 
period. Out of this number, 9 have had at least a 
follow up visit. We assume that the remaining 
had no reason to return to the clinic before their 
scheduled follow up visit at one year. Therefore, 
349 women who were due for at least their first 
follow up visit did not return. This represents a 
28.2% loss to follow up rate. They were 
however very similar to those women who came 
for follow up in their socio-demographic 
profiles and their delivery history. Nine hundred 
women had at least one follow up visit after 
insertion of implanon. They were all exposed to 
the implanon for 2006.6 woman-years or 24,079 
cycles. The mean number of months of exposure 
to the implant was 27.0 ± 14.7 months. The 
cumulative continuation rates in this study were 
78.4%, 54.5% and 21.6% at 1, 2 and 3 years 
respectively.
Over 650 women had their implant removed for 
various reasons. Table 4 shows the different 
reasons proffered for implanon removal. Over a 
third (36.1%) of the women had the implant 
removed on account of wanting another child. 
Amongst those who changed to another method, 
just under half (48.2%) changed to Jadelle, 
another implant, while over a quarter (26.2%) 
changed to an injectable. The Intrauterine 
contraceptive device (IUCD), condoms and 
pills were switching destinations for 12.8%, 
4.3% and 3.7% respectively. In 8 (4.9%) 
women, the new method was not stated.
a*  Changed to Jadelle, Injectables, IUCD, 
Condoms, Pills
b*  Divorced or widowed
 c * Others: low libido, method failure, breast 
lump, menopause, ill health, dysmenorrhoea, 
loss of last baby, thyroid enlargement, pain at site 
of insertion
There were 7 in-treatment pregnancies that 
occurred while using implanon in this study. This 
gives a pearl index of 0.35. Ultrasonography for 
dating of the pregnancies however confirmed 
that 6 out of these 7 women were most probably 
pregnant before the insertion of the implanon. 
The only woman who probably had a method 
failure had a negative urine pregnancy test at 
baseline. This became positive at six weeks. She 
weighed 51kg at the time the method failed.
Table 4: Showing the reasons for the removal of 
implanon
Reasons for Removal No. Percentage


























Husband Requests Removal  26   4.0  
Weight Gain    25   3.8  


























 TOTAL 656 100
5kg and above. Four percent of the reasons for 
removal of the implant were partner's request. 
This reflects the dorminant role that men play in 
their wives' accepting or continuing with a 
contraceptive method in our deeply patriarchal 
7
region .
A high rate of loss to follow up was another 
major observation in this study with well over a 
quarter of the acceptors failing to return to the 
clinic. While this may be an indirect measure of 
satisfaction with the method for some of the 
clients, this exposes one of the defects of service 
provision in our family planning unit. This has to 
do with the absence of a mechanism to track and 
remind clients about their follow up 
appointments to the clinic and indeed the 
approaching due date for the removal of the 
implants. Other researchers have also found that 
loss to follow up was very common in normal 
practice outside the somewhat artificial context 
29
of clinical trials . Some of our clients may 
therefore be carrying their implants many years 
after its expiration date. This was the experience 
in our unit with Norplant where some women 
were known to have deliberately carried their 
Norplant for 13 years (unpublished data).
This study has a high external validity since it 
looked at real-life situations which are radically 
different from the conditions in clinical trials 
where stringent inclusion criteria eliminated 
many categories of women. For instance, in 
most of the clinical trials on implanon, the 
implant was only inserted between days 1 to 5 of 
the menstrual cycle. This completely eliminated 
the possibility of an ongoing pregnancy before 
the insertion of the implant. Also women who 
were more than 130% of their normal body 
weight were purposively excluded from most 
29
clinical trials .
As earlier mention, the continuation rate for 
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DISCUSSION
Women who accepted implanon in our study 
tended to be somewhat more educated with 
85.5% having upto secondary school education 
or more. There was also a preponderance of 
Christian acceptors of implanon (87.8%) in the 
cohort than their Muslim counterparts (12.2%). 
Putting religion in context, 54.4% and 45.6% 
respectively of antenatal clinic attendees in 2007 
were Muslims and Christians respectively. Yet 
implanon was accepted by 19.1% and 80.9% of 
Muslims and Christians respectively in that 
year. This may be a reflection of the varying 
desire for different family sizes and/ or polygyny 
7
alluded to earlier .
A significant finding in our study was the fact 
that about 73.3% of women who accepted 
implanon have future fertility desires. This was 
despite the fact that all the women had a mean of 
2.9 children alive. This future desire for more 
children not only negatively affected the 
continuation rates for using implanon in this 
study but was also the dominant reason for 
discontinuation of the method. This was 
different from many international studies where 
the major reason for discontinuation was 
27-29
menstrual irregularities . In our study, only 62 
women (9.5%) discontinued due to menstrual 
irregularities. However, menstrual irregularity 
was the commonest cause of discontinuation 
(40.5%) in the first six months of use. Other side 
effects of implanon that led to premature 
discontinuation were weight gain (3.8%), 
elevated blood pressure (1.2%) and headache 
(1.2%). Body weight tended to increase 
significantly with implanon use in about 21% of 
30
users . Some comparative studies however 
suggested that this weight increase can only be 
31
partly attributed to the implanon . A quarter of 
the women in our study had a weight increase of 
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implanon in our study was low. The mean 
number of months of usage was 27.0 months. 
The continuation rate was 78.4% at 1 year, 
54.5% at 24 months and 21.6% by the end of the 
third year. These rates were much lower than 
those in most clinical trials where over 80.0% of 
clients were still using their implant at the end of 
two years. Continuation rates were particularly 
noted to be very high in the People's Republic of 
26China with rate of over 90% . Stringent 
inclusion and loose exclusion criteria of clinical 
trials tended to select women who had the most 
motivation and/or willingness to continue using 
29the method . Furthermore, the strict protocol of 
insertion of implanon in the first five days of the 
menstrual cycle ensures that pregnancy is 
almost completely ruled out before insertion. 
This aided the high efficacy profile seen in many 
clinical trials where no pregnancy occurred in 
over 4,103 woman-years. The Pearl index of 
32implanon was therefore 0.0 for these trials . In 
our study however, 7 in-treatment pregnancies 
occurred in 2006 woman-years giving a high PI 
of 0.35. In about 21% of the in-treatment 
failures with implanon seen during the post 
marketing surveillance study in Australia for 
27implanon, the women were already pregnant . 
In our series, six of the pregnancies were later 
proved ultrasonographically to have predated 
the implanon insertion. This seemed a drawback 
in our setting where implanon was inserted 
beyond days 1-5 of the menstrual cycle as long 
as pregnancy was thought to be reasonably 
excluded. This policy was adopted in order to 
remove all encumbrances to accepting 
implanon by reducing the number of screening 
visits for the implant. This was because whilst 
the implant itself was free, the cost of 
transportation to the clinic for multiple visits 
and opportunity cost lost with those visits could 
be prohibitively too expensive for some women.
Besides the liberal insertion of implanon beyond 
the first five days of the menstrual cycle once 
pregnancy test was 'negative', our study also had 
other methodological limitations. It was a 
retrospective review and therefore the quality of 
the data was dependent on information that was 
earlier collected within the setting of clinical 
consultation. Moreover, since some of the data 
relied on follow up visits, the fact that almost a 
quarter of the women did not return to the clinic 
may have affected the continuation rates, 
efficacy, reasons for removal and possibly other 
variables. This high rate of loss to follow up was 
compounded by the absence of a tracking system 
for the acceptors of the implant. Also, we did not 
collect data on the women's height and therefore 
we were unable to calculate the Body Mass 
Index.
Without prejudice to the above limitations 
however, this study has afforded us the 
opportunity to review and analyse our present 
clinical practice. It has given us local analysed 
data on our clients that would enhance future 
counselling of potential acceptors of implanon 
and help other providers within the Nigerian 
context.
CONCLUSION
Accepting implanon was influenced by the 
educational attainment and religion of the 
women in our unit. Implanon was used mostly 
for child spacing and the major reason for 
discontinuation in our study was the desire for 
another pregnancy. However, menstrual 
irregularity was the commonest side effect of the 
implant that led to its removal especially in the 
first six months after insertion.
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